RECRUITING Not applicable ClinicalTrials.gov

Effects of Quercetin on Cardiometabolic Outcomes

Sponsor: University of Central Lancashire • ClinicalTrials.gov ID: NCT06230861

Registry updated: 2026-09-10

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

Cardiovascular disease, type 2 diabetes mellitus and associated diseases combined are the leading health burden and cause of mortality worldwide; therefore, the necessity for an intervention is paramount. Dietary interventions to improve cardiometabolic health are highly sought after as they possess less risk than pharmacological drugs. It has been postulated that Quercetin may be beneficial in improving cardiometabolic outcomes. However, to date, no research has explored this using a placebo randomized intervention.

Interventions

Quercetin (Dietary supplement)
Quercetin tablets 400mg 1 x per day
Placebo (Other)
Placebo control 1 x blinded placebo tablet per day

Eligibility criteria

Inclusion Criteria: * Healthy * Between 18 \& 65 years * BMI \< 30 * Able to give informed consent Exclusion Criteria: * Pregnancy * Diabetes or any other metabolic/ uncontrolled hypertensive conditions * Food allergies to quercetin * Habitual consumption of quercetin * Not regularly taking medication or antioxidant supplements

Conditions

Cardiometabolic Syndrome

Locations

University of Central Lancashire — Preston, Lancashire, United Kingdom

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment